Virtu Financial LLC Invests $616,000 in Insulet Co. (NASDAQ:PODD)

Virtu Financial LLC bought a new stake in Insulet Co. (NASDAQ:PODD) in the 3rd quarter, Holdings Channel.com reports. The fund bought 2,648 shares of the medical instruments supplier’s stock, valued at approximately $616,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Blue Trust Inc. grew its stake in shares of Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 58 shares in the last quarter. Venturi Wealth Management LLC boosted its holdings in Insulet by 633.3% during the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 133 shares during the period. International Assets Investment Management LLC acquired a new position in Insulet in the 2nd quarter valued at about $32,000. UMB Bank n.a. increased its stake in Insulet by 81.0% during the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after purchasing an additional 81 shares during the period. Finally, TD Private Client Wealth LLC lifted its position in shares of Insulet by 32.6% during the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after purchasing an additional 56 shares in the last quarter.

Insider Buying and Selling

In other news, CAO Lauren Budden sold 915 shares of the stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the sale, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. This represents a 13.76 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.47% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

PODD has been the topic of several recent research reports. Piper Sandler upped their target price on shares of Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 17th. Wells Fargo & Company increased their price objective on Insulet from $290.00 to $305.00 and gave the company an “overweight” rating in a research note on Wednesday. Sanford C. Bernstein assumed coverage on Insulet in a research note on Wednesday, November 6th. They set an “outperform” rating and a $300.00 target price for the company. Raymond James upped their price target on Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a report on Monday, October 14th. Finally, BTIG Research lifted their price objective on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Three equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $267.44.

Insulet Price Performance

Shares of PODD opened at $269.34 on Friday. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $279.77. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The stock has a market cap of $18.89 billion, a PE ratio of 46.12, a price-to-earnings-growth ratio of 4.18 and a beta of 1.21. The firm has a fifty day moving average price of $251.37 and a 200 day moving average price of $220.31.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.